Science News

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.

A new interesting article has been published in PLoS One. 2018 Oct 9;13(10):e0205018. doi: 10.1371/journal.pone.0205018. eCollection 2018. and titled:

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.

Authors of this article are:
Cincinelli R1, Musso L1, Artali R2, Guglielmi MB3, La Porta I3, Melito C3, Colelli F3, Cardile F3, Signorino G3, Fucci A3, Frusciante M3, Pisano C3, Dallavalle S1.

A summary of the article is shown below:
Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivatives in combination therapies. To exploit this synergy, new hybrid molecules targeting simultaneously topoisomerase I and HDAC were designed. In particular, a selected multivalent agent containing a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.

Check out the article’s website on Pubmed for more information:



This article is a good source of information and a good way to become familiar with topics such as: n/a.

Categories: Science News